EUVIMEDEUVIMED entdecken
Open Access

Effects of Metreleptin in Patients With Generalized Lipodystrophy Before vs After the Onset of Severe Metabolic Disease

Maiah Brush, Sungyoung Auh, Elaine Cochran, Rebecca Tuska, Christopher Koh iD, David E Kleiner, Marissa Lightbourne iD, Rebecca J Brown iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae335 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Maiah Brush und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Leptin, Lipodystrophy, Congenital Generalized, Metabolic Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Leptin replacement therapy with metreleptin improves metabolic abnormalities in patients with generalized lipodystrophy (GLD).

Objective

Determine how timing of metreleptin initiation in the clinical course of GLD affects long-term metabolic health.

Methods

Retrospective analysis of patients ≥6 months old with congenital (n = 47) or acquired (n = 16) GLD treated with metreleptin at the National Institutes of Health since 2001. Least squares means for glycated hemoglobin (HbA1c), insulin area under the curve from oral glucose tolerance tests, triglycerides, urine protein excretion, platelets, transaminases, and aspartate aminotransferase (AST) to Platelet Ratio Index for early and late treatment groups, defined by baseline metabolic health, were analyzed during median 72 (24-108) months’ follow-up.

Results

Compared to late groups, early groups based on metabolic status had higher mean ± SEM insulin area under the curve (20 831 ± 1 vs 11 948 ± 1), lower HbA1c (5.3 ± 0.3 vs 6.8 ± 0.3%), triglycerides (101 ± 1 vs 193 ± 1 mg/dL), urine protein excretion (85 ± 1.5 vs 404 ± 1.4 mg/24 h), alanine aminotransferase (30 ± 1 vs 53 ± 1 U/L), AST (23 ± 1 vs 40 ± 1 U/L), and AST to Platelet Ratio Index (0.22 ± 1.3 vs 0.78 ± 1.3), and higher platelets (257 ± 24 vs 152 ± 28 K/µL) during follow-up (P < .05). Compared to patients ≥6 years old at baseline, patients <6 years had lower HbA1c (4.5 ± 0.5 vs 6.4 ± 0.2%) and higher AST (40 ± 1vs 23 ± 1 U/L) during follow (P < .05).

Conclusion

Patients with GLD who initiated metreleptin before the onset of severe metabolic complications had better long-term control of diabetes, proteinuria, and hypertriglyceridemia. Early treatment may also result is less severe progression of liver fibrosis, but further histological studies are needed to determine the effects of metreleptin therapy on liver disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeptinLipodystrophy, Congenital GeneralizedMetabolic DiseasesHumansRetrospective StudiesMaleFemaleAdultAdolescentGlycated HemoglobinChildYoung AdultChild, PreschoolInfantFollow-Up StudiesTreatment OutcomeMiddle AgedLipodystrophyInsulinTriglycerides

Stichwörter der Autor:innen

hypertriglyceridemialeptinlipoatrophic diabeteslipodystrophymetabolic associated steatotic liver disease

Substanzen

metreleptinLeptinGlycated HemoglobinInsulinTriglycerides

Autor:innen und Institutionen

  • National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.

ORCID-Profile: Christopher Koh, Marissa Lightbourne, Rebecca J Brown

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Brush, M., Auh, S., Cochran, E., Tuska, R., Koh, C., Kleiner, D. E., Lightbourne, M., & Brown, R. J. (2025). Effects of Metreleptin in Patients With Generalized Lipodystrophy Before vs After the Onset of Severe Metabolic Disease. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae335

Vancouver

Brush M, Auh S, Cochran E, Tuska R, Koh C, Kleiner DE, et al. Effects of Metreleptin in Patients With Generalized Lipodystrophy Before vs After the Onset of Severe Metabolic Disease. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae335

BibTeX
@article{Brush2025,
  author = {Brush, Maiah and Auh, Sungyoung and Cochran, Elaine and Tuska, Rebecca and Koh, Christopher and Kleiner, David E and Lightbourne, Marissa and Brown, Rebecca J},
  title = {Effects of Metreleptin in Patients With Generalized Lipodystrophy Before vs After the Onset of Severe Metabolic Disease},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae335}
}
Kostenlos starten →